FDA Approves Once-Monthly Subcutaneous Olanzapine for Schizophrenia

The FDA approved Teva's Weltruza, a once-monthly subcutaneous olanzapine injection for schizophrenia that requires no loading doses, oral supplementation, or postinjection monitoring, based on the positive results of the phase 3 SOLARIS trial.

This Wire brief sits within Fusion42's coverage of Biotech, and 14 sources have reported it between 9 Oct 2026 and 10 Oct 2026.